News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Researchers pioneer lymphoma treatment

Australian & New Zealand researchers pioneer world-first new standard of care for early stage lymphoma patients

In a world-first breakthrough for early stage low-grade lymphoma, set to change the management of the disease worldwide, an international clinical trial has found that patients live longer without a relapse with immuno-chemotherapy plus radiotherapy treatment rather than radiotherapy alone.

The results of the international phase III TROG 99.03 clinical trial will be presented today during a Plenary Session at the 2016 American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston, U.S.

The primary aim of the trial was to see if, by adding immuno-chemotherapy to the standard treatment of radiotherapy alone, outcomes could be improved for patients with stage I-II low-grade follicular lymphoma. Patients were randomised to one of two arms; radiotherapy alone or radiotherapy followed by six cycles of Cyclophosphamide, Vincristine, Prednisolone (CVP) or in the later part of the trial, Rituximab and CVP (R-CVP).

Australian Trial Co-Chair and Peter MacCallum Cancer Centre Radiation Oncologist, Professor Michael MacManus, said that the multi-centre international study, which accrued 150 participants across Australia, New Zealand and Canada, was the first of its kind to be conducted and will help define the standard of care for these patients.

“The role of effective additional multi-agent drug or ‘systemic’ therapy combined with radiotherapy has never been effectively studied before, despite the pressing need for a study like this,” Professor MacManus said.

“This is a slow-growing lymphoma and in the short term, the prognosis is good. Radiotherapy can cure around half of these patients. However, more than half of the patients will eventually relapse after radiotherapy alone, generally outside the area of the body treated with radiotherapy. Although the disease may then respond well to further therapy, most patients will eventually die from lymphoma after their relapses.

“It is clear from the trial results that radiotherapy plus R-CVP, is associated with a much better chance that patients will survive to 10 years without a relapse. It is likely to mean that the cure rate will be much higher.

“No group anywhere in the world has ever managed to complete a trial comparing radiotherapy alone with radiotherapy and multi-agent chemotherapy or immuno-chemotherapy before. The long natural history of the disease makes it very difficult to perform randomised trials in these patients, because it takes many years to know if their treatment has been effective. Few trials groups can sustain a trial over the more than 15 years that would be required to answer the question. Our trial has run for 16 years.

“Overnight, this trial will transform our knowledge of the comparative effectiveness and toxicity of two very different treatment strategies for these patients. The results of this trial will immediately inform every discussion of treatment strategy for every patient with stage I-II follicular lymphoma in the developed world.”

The trial was a collaboration between TROG Cancer Research and the Australasian Leukaemia and Lymphoma Group.

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Review: Howard Davis On Olivier Assayas' 'Personal Shopper'

Olivier Assayas’ Personal Shopper is stylish, mysterious, and very strange indeed. It manages to be both ghost story and suspense thriller, yet also a portrait of numbed loneliness and ennui , held together by an peculiarly inexpressive performance from ... More>>

Howard Davis: Never Too Old To Rock & Roll - Jethro Tull

As Greil Marcus recently observed in an NYRB review of Robbie Robertson's autobiographical Testimony, in rock and roll there is always an origin story. In the case of Jethro Tull founder Ian Anderson, he claims to have been influenced by his father's big band and jazz record collections and the emergence of rock music in the 1950s, but became disenchanted with the "show biz" style of early US stars like Elvis Presley... More>>

October: Alice Cooper Returns To NZ

It was March 1977 when Alice Cooper undertook his first ever concert tour of New Zealand – and broke attendance records. 40 years on and this revered entertainer continues to surprise and exude danger at every turn, thrilling audiences globally! More>>

ALSO:

Howard Davis Review: The Contemporary Relevance Of Denial

Denial has all the hallmarks of a riveting courtroom drama. Based on a 1996 British libel case that author David Irving brought against Lipstadt, the movie has been criticized as flat and stagey, but it nonetheless conveys a visceral clarity of vision and sense of overwhelming urgency. More>>

Obituary: John Clarke Dies Aged 68

Andrew Little: “I grew up with Fred Dagg and I am devastated by John Clarke’s death. He taught us to laugh at ourselves and more importantly laugh at our politicians.” More>>

ALSO:

Howard Davis: Colin McCahon's 'on Going Out With The Tide'

Curated by Wystan Curnow and Robert Leonard, On Going Out with the Tide features major works that have been assembled from public and private collections across New Zealand and Australia. It focusses on McCahon’s evolving engagement with Māori subjects and themes, ranging from early treatments of koru imagery to later history paintings which refer to Māori prophets and investigate land-rights issues. More>>

Howard Davis: Rodger Fox Gets Out The Funk

By now a living New Zealand legend, band leader and trombonist Rodger Fox has performed with some of the biggest names in the jazz business, including Louie Bellson, Bill Reichenbach, Chuck Findley, Randy Crawford, Bobby Shew, Lanny Morgan, Bruce Paulson, Diane Schuur, Arturo Sandoval, David Clayton-Thomas, and Joe Williams, to name only a few. More>>

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news